Regenxbio and Nippon Shinyaku collaborate to develop and commercialize gene therapies for Mucopolysaccharidosis I and II
The US gene therapy company Regenxbio and the Japanese firm Nippon Shinyaku have joined forces to boost the development and commercialization of Regenxbio’s gene therapies RGX-121 for the treatment of Mucopolysaccharidosis II (MPS II) and RGX-111 for...
